Clinical trial data readouts for anito-cel in multiple myeloma (efficacy rates, duration of response, safety profile versus existing CAR-T therapies)
FDA regulatory milestone announcements (IND clearances, BLA submissions, priority review designations, approval decisions)
Partnership or licensing deals for D-Domain platform technology (upfront payments, milestone structures, royalty rates)
Capital raises and cash runway updates (dilution concerns versus funding adequacy for trial completion)
low - Clinical trial timelines and FDA regulatory processes are largely insulated from GDP fluctuations. However, severe recessions can impact: (1) ability to raise capital at attractive valuations, (2) partnership deal flow as pharma companies tighten M&A budgets, (3) patient enrollment if economic stress affects healthcare access.
Rising rates negatively impact valuation through higher discount rates applied to distant future cash flows (anito-cel revenue likely 2027+ if approved). Clinical-stage biotechs with no near-term earnings are particularly sensitive to rate changes as their value derives entirely from NPV of long-dated projections. Higher rates also increase cost of capital for future financing rounds. With 3.99x current ratio and minimal debt (0.12 D/E), financing costs are not a material operational concern currently.
Binary regulatory risk: FDA rejection or clinical trial failure would eliminate near-term value given single lead asset concentration in anito-cel
Competitive intensity in multiple myeloma CAR-T space with established products (Abecma, Carvykti) and 10+ programs in development creating crowded market with pricing pressure
Manufacturing complexity and scalability challenges inherent to autologous cell therapies limiting commercial potential versus off-the-shelf allogeneic approaches
growth - Pure speculation on binary clinical and regulatory outcomes with no current earnings or dividends. Attracts biotech specialists, venture-style investors comfortable with high risk/high reward profiles, and momentum traders around data catalysts. The -22% three-month return reflects typical volatility around clinical readouts or sector rotation.
Trend
+37.2% vs SMA 50 · +91.0% vs SMA 200
Momentum
Accumulation pattern present — more buying days than selling over the past 20 sessions. Volume conditions support gradual price improvement.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
ANALYST ESTIMATES
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $33.0M $21.5M–$63.4M | — | -$4.05 | — | ±9% | High13 |
FY2026(current) | $73.3M $17.6M–$158.6M | ▲ +122.5% | -$3.67 | — | ±50% | High7 |
FY2027 | $261.7M $203.2M–$306.2M | ▲ +256.8% | -$1.71 | — | ±50% | High9 |
INSTITUTIONAL OWNERSHIP
ACLX News
About
Arcellx Inc. is a clinical-stage biotechnology company. The Company is focused developing controllable cell therapies for the treatment of patients with cancer and other incurable diseases.
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
ACLX◀ | $115.07 | +0.02% | $6.7B | — | -7935.3% | -102725.5% | 1500 |
| $66.13 | -5.07% | $13.0B | — | +12626.1% | -14525.8% | 1500 | |
| $94.92 | -3.79% | $12.6B | — | +3288.2% | -4239.0% | 1500 | |
| $523.69 | -3.00% | $12.1B | — | +43205.3% | -3008.0% | 1500 | |
| $227.72 | -1.30% | $11.7B | — | +6554.5% | -2868.8% | 1500 | |
| $57.90 | -0.86% | $11.2B | 50.3 | +1459.3% | 147.7% | 1500 | |
| $76.67 | -3.79% | $10.8B | — | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -2.54% | — | 50.3 | +340716.2% | -18177.0% | 1500 |